<DOC>
	<DOCNO>NCT01949948</DOCNO>
	<brief_summary>BACKGROUND : Alteplase dissolve blood vessel clot acute ischemic stroke approve acute drug treatment &lt; 4½ hour stroke onset . The overall benefit alteplase substantial , 2/3 patient large artery clot may achieve reopen vessel 40 % patient may remain severely disabled die , leave substantial room improvement . Tenecteplase , widely use coronary heart disease , may effective may less bleed complication alteplase , may drug choice also stroke . HYPOTHESIS : Tenecteplase may give safely patient acute ischemic stroke dose associate improved clinical outcome compare exist treatment option . AIMS : To compare efficacy safety tenecteplase vs. alteplase give &lt; 4½ hour symptom onset . STUDY ENDPOINTS : The primary study endpoint excellent clinical outcome 3 month ( effect ) . Secondary study endpoint major early clinical improvement ( effect ) bleeding complication ( safety ) .</brief_summary>
	<brief_title>Study Tenecteplase Versus Alteplase Thrombolysis ( Clot Dissolving ) Acute Ischemic Stroke</brief_title>
	<detailed_description>HYPOTHESIS : 1 ) Tenecteplase 0.4 mg/kg may give safely patient acute ischaemic stroke &lt; 4½ hour stroke onset . 2 ) Tenecteplase 0,4 mg/kg ( single bolus ) superior efficacy safety compare alteplase 0.9 mg/kg ( 10 % bolus + 90 % infusion/60 minute ) give within 4 ½ hour stroke onset . DESIGN : NOR-TEST multi-centre PROBE ( prospective randomise , open-label , blind endpoint ) trial randomisation tenecteplase : alteplase 1:1 . POWER CALCULATION : NOR-TEST aim detect 9 % high percentage excellent outcome tenecteplase vs. alteplase ( r1=0.40 ; r2=0.49 ; OR 1.44 ; power 0.8 ) , include 954 patient 3 year . PATIENT RECRUITMENT : All patient find eligible thrombolytic therapy eligible NOR-TEST , i.e . NOR-TEST change neither inclusion exclusion criterion . The number patient treat participate centre therefore essentially remain unchanged . Estimated 400 patient thrombolysed per year participating centre . Allowing 20 % patient include NOR-TEST , total number patient ( n=954 ) still meet .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>Age 18 year old Ischaemic stroke measurable deficit NIH Stroke Scale All stroke subtypes , severity vascular distribution , visible arterial occlusion require inclusion Treatment within 4 ½ hour stroke onset Patients awaken symptom define time last observed normal awake Informed write consent sign patient , verbal consent patient witness nonparticipating health care person , consent signature patient 's family must provide Patients premorbid modify Rankin Scale ( mRS ) score ≥3 Patients complete NIH Stroke Score obtain Hemiplegic migraine arterial occlusion CTA Seizure stroke onset visible occlusion baseline CTA Intracranial haemorrhage baseline CT Clinical presentation suggest subarachnoid haemorrhage even baseline CT normal Large area hypodense ischaemic change baseline CT Patients systolic blood pressure &gt; 185 mm Hg diastolic blood pressure &gt; 110 mm Hg Female , pregnant breast feed Known bleed diathesis Use oral anticoagulant International Normalized Ratio ( INR ) ≥1,4 Use new oral anticoagulant ( NOAC ) within last 12 hour Heparin &lt; 48 hour increase Activated partial thromboplastin tike ( APTT ) Low molecular weight heparin ( oid ) &lt; 24 hour Any investigational drug &lt; 14 day Sepsis Patients arterial puncture noncompressible site lumbar puncture &lt; 7 day Major surgery serious trauma &lt; 14 day Gastrointestinal urinary tract hemorrhage &lt; 14 day Clinical stroke &lt; 2 month History intracranial haemorrhage Brain neurosurgery &lt; 2 month Serious head trauma &lt; 2 month Pericarditis Any serious medical illness likely interact treatment Confounding preexistent neurological psychiatric disease Unlikely complete followup Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>treatment , intervention , thrombolysis</keyword>
</DOC>